At SalubrisBio, our mission is to develop first-in-class biologics that improve the health and quality of life of people living with complicated diseases.
We have the passion, commitment, and expertise needed to drive our assets through all phases of clinical development to deliver novel biologic therapies to patients. We believe we can achieve our ambitions by embracing challenges and valuing teamwork.
SalubrisBio is the first company in the world to bring a bispecific antibody into clinical trials in a cardiovascular indication. We endeavor to make this the first of many global innovation achievements.
Chief Executive Officer
Sam has worked at Salubris for over four years – joining the company as VP and Head of International Business Development, and subsequently taking an additional role as Chief Business Officer. Prior to joining Salubris, Sam worked for more than ten years in strategy consulting and transaction advisory services across several global firms, most recently as a Senior Principal at IMS (now IQVIA). Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on business development and market access. Sam completed his PhD in Virology at the University of Pennsylvania and his Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at Children’s Hospital of Philadelphia. Sam currently also serves as Chairman of the Board at GO Therapeutics, Board Director at MedAlliance SA and Viracta Therapeutics, and a Board Observer at Mercator Medsystems. He is an author of >20 peer-reviewed publications and an inventor on several issued patents.
Arian Pano, MD
Chief Medical Officer
Arian Pano, MD, comes to SalubrisBio from Kiniksa Pharmaceuticals, where he served as SVP of Clinical Development, overseeing all functional groups, including MDs, research, clinical operations, regulatory, safety, biometrics, and medical writing. Previously he served as SVP of Clinical Development for Galapagos NV, and concurrently served as the US country head and Global Head of Safety.
Dr. Pano has an extensive background in Research and Development with a focus on cardiovascular, metabolic rare diseases, inflammation and fibrosis. He has held several clinical development positions at a number of pharmaceutical companies, including Elpidera, a subsidiary of Moderna, Dicerna Pharmaceuticals, Shire and Pfizer. His technical experience covers small molecule, protein therapeutics, chaperone, mRNA based and siRNA therapeutics. Earlier in his career, he worked on medical devices/microsphere technology for cardiovascular applications.
Dr. Pano earned his MD degree from the University of Tirana, Albania, where he also completed fellowships in invasive cardiology and pediatrics. In addition, he holds an MPH in Healthcare Management from Harvard’s School of Public Health.
Interim Chief Financial Officer
Mr. DiPalma is interim Chief Financial Officer and leads all financial and fiscal planning operations for SalubrisBio.
Mr. DiPalma has over 35 years of experience in financial management and capital formation in the life sciences industry. He is currently a managing director of Danforth Advisors, LLC, a financial consultancy that specializes in working with life sciences companies. Prior to and during his tenure at Danforth, Steve has served as Chief Financial Officer to a number of public companies, in addition to many private companies in various stages of development. Immediately prior to joining Danforth in 2014, he served as Chief Financial Officer at Forum Pharmaceuticals from 2009 to 2014. He holds a Bachelor of Science from the University of Massachusetts and a Master in Business Administration from Babson College.
Dr. Jinhua Feng
Dr. Jinhua Feng joined SalubrisBio in 2017 as the Director of Research and Development. She quickly rose to Vice President, taking charge of analytical and formulation development in-house and outsourcing GMP manufacturing and QC testing. Prior to joining SalubrisBio, Dr. Feng spent more than fifteen years at MedImmune/AstraZeneca, where she concentrated on analytical method development, product characterization and structure/function relationship of monoclonal antibodies and fusion proteins, including Synagis and motavizumab. Her contributions were critical for understanding stabilizing immunoglobulin, photo-induced oxidation, charge variants, and color change of drug products. During her tenure, she also assumed CMC analytical leadership for the production of multiple pipeline programs, including the first monoclonal antibody program transferred to China and the first bispecific ADC program in the company.
Dr. Feng completed her doctorate in Analytical Chemistry from Utah State University and her Post-Doctoral Fellowship at Nebraska Center for Mass Spectrometry.
Naimish Pandya, MD
Medical Lead, JK08
Naimish Pandya, MD, is a board-certified medical oncologist, physician-scientist, and immunotherapy drug developer with more than 17 years of progressive oncology and immuno-oncology clinical development experience. He is former faculty of the University of Maryland Greenebaum Comprehensive Cancer Center, where he led the gastroenterology oncology division and spearheaded multi-specialty-based clinical trials. Subsequently, Dr. Pandya transitioned his career full-time to industry and most recently served as Vice President & Head of Clinical Development at NexImmune, where he oversaw the company’s multi-antigen T cell therapy and progressed products into early clinical development. He previously held senior clinical leadership positions at Northern Biologics and MacroGenics. Dr. Pandya also served in varying roles and leadership at MedImmune/AZ, along with consulting leadership roles at GSK, Incyte and several start-up biotech companies. In these positions, he focused on developing and progressing various IO and targeted therapies, including small molecules, monoclonal antibodies, bispecifics, and oncolytic viruses in both solid tumors and heme malignancies.
Throughout his career, Dr. Pandya has developed oncologic and rheumatologic drug candidates and managed all phases of clinical trials. He has successfully taken many preclinical molecules through an IND launch and developed and executed numerous first-in-human Phase 1 trials. Similarly, he has led multiple global Phase 2 and Phase 3 clinical trials in oncology.
Dr. Pandya received his medical degree from Temple University and completed his oncology training at Thomas Jefferson University in Philadelphia.
We focus exclusively on developing novel, complex biologic therapeutics that will provide clinically meaningful improvements in disease burden and quality of life for patients with significant medical needs.
Our disease targets are in cardiovascular disease, oncology, and neurodegenerative disease, three leading causes of death in the world today.
SalubrisBio was founded in August 2016 as a wholly-owned subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in the US, SalubrisBio reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market, and retains the core philosophy of developing therapeutics for large patient populations with significant unmet needs.